Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment Designation

Clin J Am Soc Nephrol. 2024 Oct 8. doi: 10.2215/CJN.0000000583. Online ahead of print.
No abstract available

Grants and funding